Scarica l'app Stockscreener
17.80
4.09%
0.70
Dopo l'orario di chiusura:
17.59
-0.21
-1.18%
Adma Biologics Inc Borsa (ADMA) Ultime notizie
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
New Strong Buy Stocks for October 7th - MSN
Live Scanner Shows Breakout on ADMA Biologics Inc.2025 Pullback Review & Target Return Focused Stock Picks - kangso.co.kr
ADMA Biologics Shares Surge Amid Market Optimism - TipRanks
ADMA Biologics Inc. Added to Custom Quant Screener TodayForecast Cut & Fast Exit Strategy with Risk Control - metrotimes.co.kr
Adma Biologics CEO Adam Grossman sells $354k in shares By Investing.com - Investing.com Canada
Adma Biologics CEO Adam Grossman sells $354k in shares - Investing.com
Published on: 2025-08-15 19:06:15 - thegnnews.com
ADMA Biologics (NASDAQ:ADMA) Is Posting Healthy Earnings, But It Is Not All Good News - 富途牛牛
Why ADMA Biologics Inc. stock attracts strong analyst attentionFree Double Return Watchlist - thegnnews.com
ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth - MSN
How did ADMA's revenue surge in Q4 2024 impact its profitability? - AInvest
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
Is ADMA Biologics Inc. forming a double bottomHigh Octane Equity Watchlist - newsyoung.net
Insider Sellers Might Regret Selling ADMA Biologics Shares at a Lower Price Than Current Market Value - 富途牛牛
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
ADMA Biologics Thrives With Blockbuster Growth And New FDA Edge - Finimize
ADMA Biologics Earnings Call Highlights Robust Growth - The Globe and Mail
ADMA Biologics' Stock Underperforms After Q1 Results - AInvest
ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics 2025 Q2 Earnings Strong Performance as Net Income Rises 6.7% - AInvest
ADMA Biologics Secures $300M Credit Agreement with JPMorgan - AInvest
ADMA Biologics Rides ASCENIV Demand To Higher Guidance - Finimize
ADMA Biologics Outpaces Expectations With Upbeat Growth Plans - Finimize
Noteworthy Thursday Option Activity: ADMA, SMMT, ICHR - Nasdaq
ADMA Biologics Sees Promising Gains Amid Strategic Shifts and Rising Market Trends - timothysykes.com
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
ADMA Beats On Q2 Earnings And Revenues, Asceniv Drives Momentum - Barchart.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations - Investing.com
ADMA Biologics Inc earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Adma Biologics (ADMA) Q2 Revenue Up 14% - AOL.com
ADMA Biologics Reports Strong Q2 2025 Results - TipRanks
ADMA Biologics Q2 2025 Earnings Call Transcript - MarketBeat
ADMA Biologics (ADMA) Projects Significant Growth with Yield Process and Refinancing - GuruFocus
ADMA Biologics: A Tale of Two Narratives—Strong Fundamentals vs. a Pessimistic Rating - AInvest
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics - AInvest
ADMA Biologics Q2 2025 Earnings Call Transcript Review - AInvest
ADMA Biologics' Q2 2025 Earnings and Strategic Outlook: Navigating Insider Sales and Risk Disclosures for Long-Term Value - AInvest
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):